What we are studying
The purpose of this study is to compare the effects, good and/or bad, of a new drug, either alone or in combination with the drug rituximab, with the standard treatment for this disease. The standard treatment is chemotherapy with the drug bendamustine in combination with the drug rituximab. The effects on you and your leukemia will be looked at to find out which treatment is better. Both bendamustine and rituximab are approved by the FDA to treat chronic lymphocytic leukemia (your leukemia type), but the study drug is considered investigational. In this study, you will get either the study drug alone, or study drug with rituximab, or bendamustine with rituximab. If you are in the group that receives bendamustine with rituximab and your disease returns, you will have the option to receive the study drug.